Kebuzone

Identification

Generic Name
Kebuzone
DrugBank Accession Number
DB08940
Background

Kebuzone (also known as ketophenylbutazone ) is a non-steroidal anti-inflammatory drug.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 322.3578
Monoisotopic: 322.131742452
Chemical Formula
C19H18N2O3
Synonyms
  • Kebuzone
  • ketophenylbutazone
  • quebuzona

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirKebuzone may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Abciximab.
AcebutololKebuzone may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Kebuzone.
AcemetacinThe risk or severity of adverse effects can be increased when Kebuzone is combined with Acemetacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Rheumesser 3 ml - AmpullenKebuzone (450 mg/3mL) + Cyanocobalamin (2.5 mg/3mL) + Dexamethasone (3.5 mg/3mL) + Lidocaine (5 mg/3mL) + Salicylamide O-acetic acid (150 mg/3mL)Injection, solutionIntramuscularG.L. Pharma Gmb H1983-08-29Not applicableAustria flag

Categories

ATC Codes
M01AA06 — Kebuzone
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzene and substituted derivatives. These are aromatic compounds containing one monocyclic ring system consisting of benzene.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Not Available
Direct Parent
Benzene and substituted derivatives
Alternative Parents
Pyrazolidinones / 1,3-dicarbonyl compounds / Ketones / Carboxylic acid hydrazides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
1,3-dicarbonyl compound / Aromatic heteromonocyclic compound / Azacycle / Carbonyl group / Carboxylic acid derivative / Carboxylic acid hydrazide / Hydrocarbon derivative / Ketone / Monocyclic benzene moiety / Organic nitrogen compound
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrazolidines, methyl ketone (CHEBI:31749)
Affected organisms
Not Available

Chemical Identifiers

UNII
4VD83UL6Y6
CAS number
853-34-9
InChI Key
LGYTZKPVOAIUKX-UHFFFAOYSA-N
InChI
InChI=1S/C19H18N2O3/c1-14(22)12-13-17-18(23)20(15-8-4-2-5-9-15)21(19(17)24)16-10-6-3-7-11-16/h2-11,17H,12-13H2,1H3
IUPAC Name
4-(3-oxobutyl)-1,2-diphenylpyrazolidine-3,5-dione
SMILES
CC(=O)CCC1C(=O)N(N(C1=O)C1=CC=CC=C1)C1=CC=CC=C1

References

General References
  1. Maurer HH, Tauvel FX, Kraemer T: Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. J Anal Toxicol. 2001 May-Jun;25(4):237-44. [Article]
Human Metabolome Database
HMDB0041914
KEGG Drug
D01567
PubChem Compound
3824
PubChem Substance
310264907
ChemSpider
3692
RxNav
28198
ChEBI
31749
ChEMBL
CHEMBL2107720
ZINC
ZINC000100004242
Wikipedia
Kebuzone

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.113 mg/mLALOGPS
logP1.99ALOGPS
logP2.7Chemaxon
logS-3.4ALOGPS
pKa (Strongest Acidic)4.57Chemaxon
pKa (Strongest Basic)-7.3Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area57.69 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity89.37 m3·mol-1Chemaxon
Polarizability33.64 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-000x-9451000000-20f6c914fed406957207
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00dl-1039000000-8f24bd3128fe208b2146
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0009000000-ace89141a95d00525042
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-060r-0269000000-9c187ed821c915d4fed6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0v0r-1977000000-b17f43d926d9cd166e94
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-5890000000-2d1c93f16e70c93b6f11
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0159-5911000000-a512f0aad8e973d1d464
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-189.878883
predicted
DarkChem Lite v0.1.0
[M-H]-191.252183
predicted
DarkChem Lite v0.1.0
[M-H]-173.53279
predicted
DeepCCS 1.0 (2019)
[M+H]+190.933883
predicted
DarkChem Lite v0.1.0
[M+H]+191.428283
predicted
DarkChem Lite v0.1.0
[M+H]+175.8908
predicted
DeepCCS 1.0 (2019)
[M+Na]+190.161483
predicted
DarkChem Lite v0.1.0
[M+Na]+190.592483
predicted
DarkChem Lite v0.1.0
[M+Na]+182.53542
predicted
DeepCCS 1.0 (2019)

Drug created at May 26, 2014 21:08 / Updated at February 21, 2021 18:52